| A single-cell atlas of the tumor and immune ecosystem of human breast cancer J Wagner, MA Rapsomaniki, S Chevrier, T Anzeneder, C Langwieder, ... Cell 177 (5), 1330-1345. e18, 2019 | 720 | 2019 |
| PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors KJ Dedes, D Wetterskog, AM Mendes-Pereira, R Natrajan, MB Lambros, ... Science translational medicine 2 (53), 53ra75-53ra75, 2010 | 410 | 2010 |
| Emerging therapeutic targets in endometrial cancer KJ Dedes, D Wetterskog, A Ashworth, SB Kaye, JS Reis-Filho Nature reviews Clinical oncology 8 (5), 261-271, 2011 | 335 | 2011 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 270 | 2022 |
| Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised … JS Vaidya, M Bulsara, M Baum, F Wenz, S Massarut, S Pigorsch, ... bmj 370, 2020 | 259 | 2020 |
| Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations KJ Dedes, PM Wilkerson, D Wetterskog, B Weigelt, A Ashworth, ... Cell cycle 10 (8), 1192-1199, 2011 | 239 | 2011 |
| ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas EP Samartzis, A Noske, KJ Dedes, D Fink, P Imesch International journal of molecular sciences 14 (9), 18824-18849, 2013 | 207 | 2013 |
| Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer KJ Dedes, R Natrajan, MB Lambros, FC Geyer, MA Lopez-Garcia, ... European journal of cancer 47 (1), 138-150, 2011 | 194 | 2011 |
| Functional viability profiles of breast cancer R Brough, JR Frankum, D Sims, A Mackay, AM Mendes-Pereira, I Bajrami, ... Cancer Discovery 1 (3), 260-273, 2011 | 173 | 2011 |
| Loss of ARID1A expression sensitizes cancer cells to PI3K-and AKT-inhibition EP Samartzis, K Gutsche, KJ Dedes, D Fink, M Stucki, P Imesch Oncotarget 5 (14), 5295, 2014 | 155 | 2014 |
| Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer MD Forster, KJ Dedes, S Sandhu, S Frentzas, R Kristeleit, A Ashworth, ... Nature reviews Clinical oncology 8 (5), 302-306, 2011 | 148 | 2011 |
| Medication non-adherence in inflammatory bowel diseases is associated with disability J Perry, A Chen, V Kariyawasam, G Collins, C Choong, WL Teh, N Mitrev, ... Intestinal research 16 (4), 571-578, 2018 | 127* | 2018 |
| Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast R Natrajan, PM Wilkerson, C Marchiò, S Piscuoglio, CKY Ng, P Wai, ... The Journal of Pathology, 2014 | 119 | 2014 |
| Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial M Colleoni, W Luo, P Karlsson, J Chirgwin, S Aebi, G Jerusalem, P Neven, ... The lancet oncology 19 (1), 127-138, 2018 | 117 | 2018 |
| Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? EP Samartzis, N Samartzis, A Noske, A Fedier, R Caduff, KJ Dedes, ... Modern Pathology 25 (6), 885-892, 2012 | 117 | 2012 |
| Impact of clinical pathways in surgery MK Müller, KJ Dedes, D Dindo, S Steiner, D Hahnloser, PA Clavien Langenbeck's archives of surgery 394, 31-39, 2009 | 109 | 2009 |
| Effect of delayed targeted intraoperative radiotherapy vs whole-breast radiotherapy on local recurrence and survival: long-term results from the TARGIT-A randomized clinical … JS Vaidya, M Bulsara, C Saunders, H Flyger, JS Tobias, T Corica, ... JAMA oncology 6 (7), e200249-e200249, 2020 | 101 | 2020 |
| A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing K Matter-Walstra, M Schwenkglenks, S Aebi, K Dedes, J Diebold, ... Journal of Thoracic Oncology 11 (11), 1846-1855, 2016 | 99 | 2016 |
| Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro R Koppensteiner, EP Samartzis, A Noske, A von Teichman, I Dedes, ... PloS one 9 (6), e100041, 2014 | 96 | 2014 |
| Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation KJ Dedes, K Matter-Walstra, M Schwenkglenks, BC Pestalozzi, D Fink, ... European Journal of Cancer 45 (8), 1397-1406, 2009 | 81 | 2009 |
Imesch PatrickUniversity Hospital Zurich, Department of GynecologyDirección de correo verificada de usz.ch
